Your session is about to expire
← Back to Search
Neurostimulation Device
Auricular Neurostimulation for Chemotherapy-Induced Nausea and Vomiting
N/A
Recruiting
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Chemotherapy regimens must include moderate and/or severe emetogenic chemotherapy
Subjects who are scheduled to be admitted for chemotherapy administration and who will have at least one additional cycle of the same chemotherapy
Must not have
Diagnosis of psoriasis vulgaris
Infection or severe dermatological condition of ear
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the date of baseline assessment up to 7 days after completion of intervention ~ day 13
Awards & highlights
Summary
This trial looks at using a nerve stimulator to reduce chemo-related nausea/vomiting in kids, teens, and young adults.
Who is the study for?
This trial is for children, adolescents, and young adults who are about to receive chemotherapy that's known to cause moderate or severe nausea and vomiting. They must have at least one more cycle of the same chemo planned. It's not for those with developmental delays affecting participation, ear infections or skin conditions, uncontrolled infections, electrical implants in their body, pregnancy, severe heart/lung disease, bleeding disorders or psoriasis vulgaris.
What is being tested?
The study is testing a device called an auricular percutaneous electrical nerve field stimulator against a sham (fake) version to see if it can reduce nausea and vomiting caused by chemotherapy. Participants will be randomly assigned to either the real treatment group or the sham control group.
What are the potential side effects?
Potential side effects may include discomfort at the site where the device attaches to the ear. Since this involves neurostimulation rather than drugs, traditional drug-related side effects are not expected.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My chemotherapy is known to cause moderate to severe nausea.
Select...
I am scheduled for chemotherapy and will have at least one more round of the same treatment.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with psoriasis vulgaris.
Select...
I have a severe ear infection or skin condition.
Select...
I have a serious heart or lung condition.
Select...
I have been diagnosed with hemophilia or another bleeding disorder.
Select...
I do not have a severe or uncontrolled infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from the date of baseline assessment up to 7 days after completion of intervention ( day 13)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the date of baseline assessment up to 7 days after completion of intervention ( day 13)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assessment of Rescue Medication
Baxter Retching Faces Scale
Change in Rhodes Index of Nausea, Vomiting and Retching (INVR)
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Active percutaneous neurostimulationActive Control1 Intervention
Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
Group II: Sham percutaneous neurostimulationPlacebo Group1 Intervention
Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
Find a Location
Who is running the clinical trial?
Medical College of WisconsinLead Sponsor
620 Previous Clinical Trials
1,172,524 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger